

Anti-Wnt Antibody (Ipafricept)

Introduction



Ipafricept is a recombinant fusion protein that acts as an inhibitor of the Wnt signaling pathway. It consists of a modified form of the extracellular domain of the human Frizzled 8 receptor (Fzd8) linked to the Fc portion of a human IgG1 antibody. This fusion protein is designed to bind to Wnt ligands, thereby preventing them from activating the Wnt signaling pathway, which is often associated with the development and progression of a variety of cancers. Ipafricept is currently in clinical trials to investigate its potential use in the treatment of solid tumors and other malignancies.

Product parameters

Alternative Names	OMP-54F28, FZD8-Fc
Target Accession	-
Target	Wnt
CA <mark>S nu</mark> mber	
Molecular Weight	Achieve Perfection, Explore the Unknown
Host	СНО
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	lgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years

Note

Note





1. This product is for scientific research use only.









APExBIO Technology www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com